Latest:
Dr. Newman on Health Disparities in Breast Cancer
Lisa Newman, MD, MPH, FACS, FASCO, chief of Breast Surgery, Weill Cornell Medical Center and NewYork-Presbyterian, discusses health disparities among women with breast cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Lisa Shomsky, BSN, MBA
Latest:
Merging Community Practices With an Academic Cancer Center
Consolidation of community oncology practices with hospital-based cancer centers is an accelerating trend that will affect future healthcare delivery models. This year, the Community Oncology Alliance reported hospital acquisitions and corporate mergers among 55% of 1338 community oncology practices surveyed, representing a 20% increase over the previous year's results.
Liza-Marie Johnson, MD, MPH, MSB
Latest:
Clinical Ethics 101: Practical Ethical Principles for Oncology Fellows
Education in medical ethics is required in medical school and residency programs, yet there is so much variability in the timing and delivery of this education and many house staff report inadequacies and gaps in their ethical training.
Loreen M. Brown, MSW
Latest:
NOW Initiative: Payer & Provider Collaborations in Oncology Benefits Management
Payers recognize the need to expand benefits management for oncology but struggle to find effective solutions amid the complexity of
available therapies and skepticism from oncologists, who are facing their own set of economic pressures. The National Oncology Working Group (NOW) Initiative is trying to change the sometimes adversarial
relationship between payers and oncologists through a collaborative model.
Loren K. Mell, MD
Latest:
Dr. Mell on Individualizing Treatment for Head and Neck Cancer
Loren K. Mell, MD, assistant professor, Department of Radiation Medicine and Applied Sciences, University of California, San Diego School of Medicine, discusses individualizing treatments for patients with head and neck cancer.
Lorenza Rimassa, MD
Latest:
Five-year Overall Survival (OS) and OS by Tumor Response Measures from the Phase 3 HIMALAYA Study of Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma (uHCC)
Dr. Lorenza Rimassa presents a five-year overall survival analysis from the Phase 3 HIMALAYA study, demonstrating sustained survival benefits of the STRIDE regimen versus sorafenib in patients with unresectable hepatocellular carcinoma (uHCC).
Loretta Nastoupil, MD
Latest:
Dr Nastoupil on the Investigation of Liso-Cel in Relapsed/Refractory Follicular Lymphoma
Loretta J. Nastoupil, MD, discusses the safety and efficacy data from the phase 2 TRANSCEND FL trial evaluating lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma.